Last reviewed · How we verify
ANX-188 Therapeutic Dose — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
ANX-188 Therapeutic Dose (ANX-188 Therapeutic Dose) — Mast Therapeutics, Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| ANX-188 Therapeutic Dose TARGET | ANX-188 Therapeutic Dose | Mast Therapeutics, Inc. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- ANX-188 Therapeutic Dose CI watch — RSS
- ANX-188 Therapeutic Dose CI watch — Atom
- ANX-188 Therapeutic Dose CI watch — JSON
- ANX-188 Therapeutic Dose alone — RSS
Cite this brief
Drug Landscape (2026). ANX-188 Therapeutic Dose — Competitive Intelligence Brief. https://druglandscape.com/ci/anx-188-therapeutic-dose. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab